Bausch & Lomb eyes global options as it cuts staff
This article was originally published in Clinica
Eye care company Bausch & Lomb is to cut 7% of its workforce by consolidating its contact lens manufacturing operations. It has highlighted other areas where further savings can be made and has also authorised the repurchase of five million shares. The value of B&L's shares rose by nearly 11% to $60.7 on the news, with a trading volume of nearly double the daily average.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.